Chromatographic analysis of purine precursors in mouse L1210 leukemia

Abstract

A number of antagonists of nucleotide metabolism with anti-cancer activity affect the de novo purine pathway. To determine the biochemical mechanisms of cytotoxicity of these drugs, assay procedures have been developed for measurement of the levels of intermediates proximal to IMP in the pathway for de novo purine biosynthesis in mouse L1210 leukemia cells. Purine precursors have been synthesized in vitro from [ 14C]-glycine using enzymes from chicken liver. These 14C-labeled intermediates have been used as marker compounds to define retention times for metabolites of leukemia cells separated by HPLC and the chromatographic mobilities of these intermediates after two-dimensional thin-layer chromatography. These new chromatographic procedures have been used in combination to determine the steady-state concentrations for purine precursors in mouse L1210 leukemia cells in the exponential phase of growth: N-formylglycineamide ribotide (16 μ m); N-formylglycineamidine ribotide (4.7 μ m); 5-aminoimidazole ribotide (4.0 μ m); 4-carboxy-5-aminoimidazole ribotide (0.46 μ m); N-succino-5-aminoimidazole-4-carboxamide ribotide (11 μ m); 5-aminoimidazole-4-carboxamide ribotide (16 μ m); 5-formamidoimidazole-4-carboxamide ribotide (2.7 μ m); and IMP (57 μ m). The metabolic effects of tiazofurin (25 μ m) upon mouse L1210 leukemia cells growing in culture define a “metabolic crossover point” at the reaction catalyzed by IMP dehydrogenase (EC 1.1.1.205) which confirms previous reports of inhibition of this enzyme.